<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602509</url>
  </required_header>
  <id_info>
    <org_study_id>Celecoxib_WBA</org_study_id>
    <nct_id>NCT02602509</nct_id>
  </id_info>
  <brief_title>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</brief_title>
  <official_title>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bactericidal activity against Mycobacterium&#xD;
      tuberculosis of celecoxib in combination with established drugs used to treat tuberculosis&#xD;
      (TB). Pharmacokinetics (PK) and whole blood bactericidal activity (WBA) will be measured in&#xD;
      healthy volunteers following administration of the study drugs alone and in combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The whole blood bactericidal activity (WBA) assay is an ex vivo model for measuring the&#xD;
      combined effects of administered drugs, host factors and strain factors on mycobacterial&#xD;
      sterilisation. If performed in parallel with PK measurements, the method can be used to&#xD;
      evaluate the effect of drugs throughout the dosing cycle. Celecoxib is a COX-2 inhibitor with&#xD;
      immuno-modulatory properties important in the host defence against tuberculosis (TB). The aim&#xD;
      of this trial is to investigate the effect on WBA of manipulation of the host response to TB&#xD;
      using celecoxib, in combination with established TB drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log change CFU.day (cumulative over 8 hours) calculated from Mycobacteria Growth Indicator Tube (MGIT) Time to Positivity</measure>
    <time_frame>8 hours</time_frame>
    <description>Cumulative whole blood bactericidal activity (WBA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of study drugs to determine the Area Under the Curve (AUC)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of study drugs to determine the Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Celecoxib plus rifampicin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib plus pyrazinamide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Celecoxib plus pyrazinamide group</arm_group_label>
    <arm_group_label>Celecoxib plus rifampicin group</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <arm_group_label>Celecoxib plus rifampicin group</arm_group_label>
    <other_name>Rifampin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <arm_group_label>Celecoxib plus pyrazinamide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged over 21 years and below 60 years old&#xD;
&#xD;
          2. Male or female willing to comply with the study visits and procedures&#xD;
&#xD;
          3. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are currently pregnant or breastfeeding&#xD;
&#xD;
          2. Body weight below 50kg&#xD;
&#xD;
          3. Clinical signs of active TB in the opinion of the investigator&#xD;
&#xD;
          4. Previous hypersensitivity, intolerance or allergy to rifampicin, pyrazinamide, COX-2&#xD;
             inhibitors, non-steroidal anti-inflammatory drugs or sulfonamides&#xD;
&#xD;
          5. Current use of any drugs or medication known to have an interaction with rifampicin,&#xD;
             pyrazinamide or celecoxib&#xD;
&#xD;
          6. Current use or use in the last 2 weeks of non-steroidal anti-inflammatory drugs or&#xD;
             COX-2 inhibitors&#xD;
&#xD;
          7. Current use or use in the last 2 weeks of any drugs, over the counter or herbal&#xD;
             preparations that are known or potential inhibitors or inducers of cytochrome P450&#xD;
             enzymes&#xD;
&#xD;
          8. Evidence of renal or hepatic dysfunction or any clinically significant deviation from&#xD;
             normal during screening including laboratory determinations&#xD;
&#xD;
          9. Known hepatic disease, recent hepatitis (within last 6 months) or alcohol abuse&#xD;
&#xD;
         10. Known cardiovascular disease, heart failure, stroke or current cardiovascular risk&#xD;
             factors&#xD;
&#xD;
         11. Known peptic ulcer disease, previous gastrointestinal bleed or current risk factors&#xD;
             for gastrointestinal events&#xD;
&#xD;
         12. Acute or previous gout, acute porphyria&#xD;
&#xD;
         13. Any other significant condition that would, in the opinion of the investigator,&#xD;
             compromise the volunteer's safety or outcome in the trial&#xD;
&#xD;
         14. Current participation in other clinical intervention trial or research protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

